Javier Cortes

Javier Cortes

UNVERIFIED PROFILE

Are you Javier Cortes?   Register this Author

Register author
Javier Cortes

Javier Cortes

Publications by authors named "Javier Cortes"

Are you Javier Cortes?   Register this Author

100Publications

4345Reads

25Profile Views

Window of Opportunity trials for biomarker discovery in breast cancer.

Curr Opin Oncol 2019 Nov;31(6):486-492

IOB Institute of Oncology, Quiron, Madrid.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000583DOI Listing
November 2019

The rise of oncology biosimilars: from process to promise.

Future Oncol 2019 Oct 23;15(28):3255-3265. Epub 2019 Aug 23.

Department of Medical Oncology, OB Institute of Oncology, Quironsalud Group, Calle Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0145DOI Listing
October 2019

Breast cancer.

Nat Rev Dis Primers 2019 Sep 23;5(1):66. Epub 2019 Sep 23.

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41572-019-0111-2DOI Listing
September 2019

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

Oncologist 2019 Aug 21;24(8):1041-1047. Epub 2018 Dec 21.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693696PMC
August 2019

The safety of eribulin for the treatment of metastatic breast cancer.

Expert Opin Drug Saf 2019 May 20;18(5):347-355. Epub 2019 May 20.

a Medica Scientia Innovation Research (MedSIR) , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2019.1608946DOI Listing
May 2019

Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations.

Int J Mol Sci 2019 Mar 1;20(5). Epub 2019 Mar 1.

BIOPHYM, Department of Macromolecular Physics, Instituto de Estructura de la Materia, IEM-CSIC, C/ Serrano 113 bis, 28006 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20051076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429128PMC
March 2019

Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.

Cancer Treat Rev 2018 Nov 21;70:190-198. Epub 2018 Aug 21.

Global Oncology, Eisai Inc., Andover, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.08.008DOI Listing
November 2018

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

J Clin Oncol 2018 Sep 20:JCO2017748392. Epub 2018 Sep 20.

Aditya Bardia, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; Scott Cameron and Serena Liao, Novartis Institutes for BioMedical Research, Cambridge, MA; Marina Parton, The Royal Marsden Hospital, London, United Kingdom; Sherko Kümmel, Kliniken Essen-Mitte, Essen, Germany; Laura G. Estévez, Centro Integral Oncológico Clara Campal; Javier Cortés, University Hospital Ramón y Cajal, Madrid; Javier Cortés,Vall d'Hebron Institute of Oncology, Barcelona; Manuel Ruiz-Borrego, Hospital Universitario Virgen del Rocío, Seville; Paloma Martin-Martorell, Hospital Clínico Universitario de Valencia, Valencia; Rafael López, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Chiun-Sheng Huang, National Taiwan University Hospital, National Taiwan University College of Medicine; Shin-Cheh Chen, Chang Gung Memorial Hospital, Taipei, Republic of China; Melinda L. Telli, Stanford University School of Medicine, Stanford; Sara A. Hurvitz, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Roohi Ismail-Khan, Moffitt Cancer Center, Tampa, FL; Ingrid A. Mayer, Vanderbilt-Ingram Cancer Center, Nashville, TN; Daniel Carreon, Novartis Pharmaceuticals Corporation, East Hanover, NJ; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.8392
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.8392DOI Listing
September 2018

CXCR4 antagonists for treatment of breast cancer.

Oncotarget 2018 Sep 11;9(71):33442-33443. Epub 2018 Sep 11.

Javier Cortés: Ramon y Cajal University Hospital, Madrid, Spain; Vall d´Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, QuironGroup, Madrid & Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173365PMC
September 2018

Reply to K.S. Shohdy et al.

J Clin Oncol 2018 08 30;36(23):2458-2459. Epub 2018 May 30.

Tiffany A. Traina, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; and Javier Cortes, Ramon y Cajal University Hospital, Madrid, and Vall d'Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.8349
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.8349DOI Listing
August 2018

Is there a role for immunotherapy in HER2-positive breast cancer?

NPJ Breast Cancer 2018 15;4:21. Epub 2018 Aug 15.

1Ramon y Cajal University Hospital, Ctra, Colmenar Viejo km. 9,100, 28034 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-018-0072-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093898PMC
August 2018

The new world of biosimilars in oncology: Translation of data to the clinic.

Eur J Cancer 2018 06 18;96:125-127. Epub 2018 Apr 18.

Ramon y Cajal University Hospital, Madrid, Spain; Vall D'Hebron Institute of Oncology, Barcelona, Spain; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.005DOI Listing
June 2018

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Lancet Oncol 2018 06 26;19(6):812-824. Epub 2018 Apr 26.

Breast Cancer Unit and Gynaecological Tumours, Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Baselga Oncology Institute, Quiron Group, Madrid and Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30147-5DOI Listing
June 2018

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

J Clin Oncol 2018 03 26;36(9):884-890. Epub 2018 Jan 26.

Tiffany A. Traina and Ayca Gucalp, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Kathy Miller, Indiana University Simon Cancer Center, Indianapolis, IN; Denise A. Yardley, Tennessee Oncology, Nashville; Lee S. Schwartzberg, The West Clinic, Memphis, TN; Janice Eakle, Florida Cancer Specialists, Fort Myers, FL; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX; William Gradishar, Northwestern University Feinberg School of Medicine; Rita Nanda, University of Chicago, Chicago; Joyce Steinberg, Astellas Pharma, Northbrook, IL; Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Catherine Kelly, All Ireland Collaborative Oncology Research Group, Dublin, Ireland; Ahmad Awada, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Laura Garcia-Estevez, Centro Integral Oncologico Clara Campal, Hospital Madrid Norte-Sanchinarro; Javier Cortes, Ramon y Cajal University Hospital, Madrid, and, Vall d'Hebron Institute of Oncology and Baselga Oncological Institute, Barcelona, Spain; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and Hirdesh Uppal, Amy Peterson, and Iulia Cristina Tudor, Medivation, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.3495
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.3495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858523PMC
March 2018

Breast cancer in 2017: Spurring science, marking progress, and influencing history.

Nat Rev Clin Oncol 2018 02 12;15(2):79-80. Epub 2017 Dec 12.

Ramon y Cajal University Hospital, Carretera Colmenar Viejo km. 9,100, 28034 Madrid, Spain; at Vall d´Hebron Institute of Oncology, Calle Natzaret 115-117, 08035 Barcelona, Spain; and at Medica Scientia Innovation Research (MedSIR), Rambla Catalunya 2, 08007 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.191DOI Listing
February 2018

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Cancer Treat Rev 2018 Feb 6;63:144-155. Epub 2017 Dec 6.

Medical Oncology Clinic, Institut Jules Bordet Universite Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.12.002DOI Listing
February 2018

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.

Biochim Biophys Acta Rev Cancer 2017 Dec 20;1868(2):527-537. Epub 2017 Oct 20.

Ramon y Cajal University Hospital, Ctra. Colmenar Viejo km. 9, 100, 28034 Madrid, Spain; Baselga Institute of Oncology, Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2017.10.003DOI Listing
December 2017

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

Cancer Treat Rev 2017 Dec 12;61:53-60. Epub 2017 Oct 12.

MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston 77030, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.09.011DOI Listing
December 2017

Advances in the management of HER2-positive early breast cancer.

Crit Rev Oncol Hematol 2017 Nov 4;119:113-122. Epub 2017 Oct 4.

University of Ulm, Ulm, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2017.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662944PMC
November 2017

Modulation of telomere protection by the PI3K/AKT pathway.

Nat Commun 2017 11 2;8(1):1278. Epub 2017 Nov 2.

Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Melchor Fernández Almagro 3, Madrid, E-28029, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-01329-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668434PMC
November 2017

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

Breast 2017 Jun 28;33:8-13. Epub 2017 Feb 28.

Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Morphological Sciences Department, Universidad Autónoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2017.02.011DOI Listing
June 2017

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Lancet Oncol 2017 04 24;18(4):545-554. Epub 2017 Feb 24.

Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30021-9DOI Listing
April 2017

Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women.

BMC Womens Health 2017 03 16;17(1):21. Epub 2017 Mar 16.

Senior Consultant on Gynecologic Oncology. Former President of the Spanish Association of Colposcopy and Cervical Pathology, Palma de Mallorca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12905-017-0374-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356315PMC
March 2017

Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.

Ann Surg Oncol 2016 11 29;23(12):3831-3837. Epub 2016 Jun 29.

Breast Surgical Oncology Unit, Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-016-5339-4DOI Listing
November 2016

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Oncotarget 2016 10;7(42):67956-67965

Breast Surgical Unit, Breast Cancer Center, Hospital Universitario Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531PMC
October 2016

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

Nat Rev Clin Oncol 2016 09 22;13(9):566-79. Epub 2016 Mar 22.

Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118200PMC
September 2016

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Cell 2016 09 15;167(1):260-274.e22. Epub 2016 Sep 15.

Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037319PMC
http://dx.doi.org/10.1016/j.cell.2016.08.041DOI Listing
September 2016

Etirinotecan pegol for the treatment of breast cancer.

Expert Opin Pharmacother 2016 10;17(5):727-34. Epub 2016 Mar 10.

a Department of Medical Oncology , Ramon y Cajal University Hospital , Madrid , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1154537DOI Listing
August 2016

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.

Cancer Metastasis Rev 2016 Jun;35(2):323-32

Baylor-Sammons Cancer Center, Texas Oncology, U.S. Oncology, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9619-zDOI Listing
June 2016

Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway.

Oncotarget 2016 May;7(19):28086-95

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Oncology Program, Vall d'Hebron Research institute, VHIR-Vall d'Hebron Hospital, Barcelona-UAB 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053711PMC
http://dx.doi.org/10.18632/oncotarget.8578DOI Listing
May 2016

Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

Oncology 2015 1;89(2):79-87. Epub 2015 Apr 1.

Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000371746DOI Listing
March 2016

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

PLoS One 2015 15;10(6):e0129876. Epub 2015 Jun 15.

Preclinical Oncology Program, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129876PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467984PMC
March 2016

Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations.

Pigment Cell Melanoma Res 2016 Mar;29(2):247-53

Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall dHebron Research Institute-VHIR Vall d'Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12452DOI Listing
March 2016

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Melanoma Res 2015 Dec;25(6):486-95

aTranslational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital bPangaea Biotech S.L cHospital Vall d'Hebron dCatalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona eMORe Foundation, Barcelona fHospital Central Asturias, Oviedo gPivotal SL, Madrid hCUN, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000187DOI Listing
December 2015

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Breast Cancer Res Treat 2015 Dec 14;154(3):509-20. Epub 2015 Nov 14.

Department of Oncology, Leeds Institute of Cancer and Pathology, and St James's Institute of Oncology, University of Leeds, Leeds, LS9 7TF, England, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3633-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661183PMC
December 2015

Influencing cancer treatment.

Lancet Oncol 2015 Dec;16(16):1591-3

University of Alcala de Henares, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00412-XDOI Listing
December 2015

Javier Cortés, MD, on the CLEOPATRA Trial.

Authors:
Javier Cortés

Oncology (Williston Park) 2015 Oct;29(10):718

View Article

Download full-text PDF

Source
October 2015

In response: Genomic profile of breast cancer.

Expert Rev Pharmacoecon Outcomes Res 2015 Jun 22;15(3):395-7. Epub 2015 Mar 22.

Medical Oncology Department, Corporació Sanitaria Parc Taulí, Sabadell, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737167.2015.1025760DOI Listing
June 2015

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015